AbbVie Inc. — Director's Dealing 2019

Jul 9, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: AbbVie Inc. (ABBV)
CIK: 0001551152
Period of Report: 2019-07-01

Reporting Person: Hudson Thomas J (SVP, R&D and CSO)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common stock, $0.01 par value	12748	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option (right to buy)	$59.50	2026-05-22	Common stock, $0.01 par value (14080)		Direct
Option (right to buy)	$61.36	2027-02-15	Common stock, $0.01 par value (15230)		Direct
Option (right to buy)	$114.36	2028-02-14	Common stock, $0.01 par value (6710)		Direct
Option (right to buy)	$79.02	2029-02-20	Common stock, $0.01 par value (15576)		Direct

Footnotes

F1: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 4,694 shares on 5/23/2017, as to 4,693 shares on 5/23/2018 and as to 4,693 shares on 5/23/2019.

F2: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 5,077 shares on 2/16/2018 and as to 5,077 shares on 2/16/2019, and becomes exercisable as to 5,076 shares on 2/16/2020.

F3: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 2,237 shares on 2/15/2019, and becomes exercisable as to 2,236 shares on 2/15/2020 and as to 2,237 shares on 2/15/2021.

F4: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable as to 5,192 shares on 2/21/2020, as to 5,192 shares on 2/21/2021 and as to 5,192 shares on 2/21/2022.